Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating treatments for adults aged 18 to 65 with acute renal colic, a condition characterized by sudden, sharp flank pain that may radiate to the genital area or groin, sometimes with urinary symptoms. The study aims to compare the effects of intravenous dexamethasone versus nebulized terbutaline, both combined with paracetamol, on managing pain in emergency settings. Participants must have a pain score of 5 or higher on a 10-centimeter scale and no serious cardiovascular, hepatic, renal, metabolic diseases, or infections. Participants are randomly assigned to one of three groups one receives paracetamol and placebo injections plus placebo nebulization, another receives paracetamol plus intravenous dexamethasone and placebo nebulization, and the third receives paracetamol plus placebo injections and nebulized terbutaline. The treatments are administered during a 10-minute nebulization session. This is a phase 3, single-blind clinical trial with a factorial design. During the study, participants pain levels will be measured using the Numeric Rating Scale NRS 120 minutes after treatment to assess a 50% reduction in pain. Researchers will also monitor adverse effects and the need for additional pain relief at this time point. The total study duration extends until March 2028, with primary outcome data expected by December 2027. Participants will undergo assessments and safety monitoring during their time in the trial.
Actively Recruiting
Acute heart failure AHF is a major cause of hospital stays and is linked to high rates of rehospitalization or death within 30 days after discharge. Current risk assessments mainly focus on blood flow congestion in large vessels, but they do not fully capture small vessel and tissue-level problems that can continue despite clinical improvement. Lung ultrasound scores LUS help assess lung congestion, while blood lactate levels indicate tissue oxygen delivery and usage. Combining these two measures may better predict early complications after hospital discharge. This observational study includes adults hospitalized for acute heart failure who are clinically stable and expected to be discharged within 24 hours. At discharge, participants undergo lung ultrasound using a standardized 8-zone method to measure lung congestion, and blood lactate levels are measured at rest. Researchers collect clinical data including patient demographics, heart failure type, vital signs, lab tests, treatments, and hospitalization details to classify patients based on combined lung congestion and tissue perfusion scores. Participants are followed for 30 days after discharge through phone interviews and medical record review to track outcomes such as heart failure readmission, emergency visits, and death. The main outcome is a combined measure of rehospitalization or all-cause mortality within 30 days. Secondary outcomes include time to first event and all-cause readmission. This follow-up helps evaluate if the combined lung ultrasound and lactate score better predicts early adverse events compared to lung ultrasound alone.
Actively Recruiting
This research aims to evaluate the impact of a telemonitoring system on managing blood sugar control in patients with diabetes in Tunisia. The study compares remote diabetes management using a specialized mobile app and web platform with standard diabetes care. The main goal is to assess if telemonitoring improves glycemic control by measuring changes in glycated hemoglobin HbA1c and blood glucose levels. Participants in the telemonitoring group will use a connected blood glucose meter that automatically sends all readings to an online telemonitoring platform. The control group will receive usual diabetes care according to standard clinical practice, including at least three scheduled visits at Day 15, Month 3, and Month 6. Both groups will have the same clinical and study data collected during these visits. During the study, participants will attend scheduled visits to monitor blood glucose, HbA1c, body weight, body mass index, urinary albumin levels, and other health markers. Medication adherence will be assessed using questionnaires and refill records. Researchers will also track hospitalizations and emergency visits. The study will last for six months, with outcomes measured from baseline to six months to evaluate the effectiveness and utility of telemonitoring in managing diabetes.
Actively Recruiting
Researchers are studying adult patients who come to the emergency department with sudden shortness of breath dyspnea to evaluate how well the CardioStory device can distinguish heart failure from other causes. This observational study collects data from routine clinical assessments, including medical history, physical exams, laboratory tests, and echocardiography results. The goal is to assess the diagnostic performance of this non-invasive technology in a real-world emergency setting. The CardioStory device is a non-invasive medical tool designed to quickly measure cardiac filling pressure using fiber-optic sensors and advanced algorithms, without the need for catheterization or injectable substances. Patients will be assessed using this device alongside standard clinical evaluations to compare results. The measurement process is rapid, taking about 2 minutes, and aims to be simple and reproducible. Participants involvement includes undergoing routine clinical assessments and the CardioStory device measurement during their emergency visit. Researchers will collect data on diagnostic accuracy, sensitivity, specificity, time required for measurements, and any adverse events related to the device on the first day. The total study duration extends until December 2026, with data collected primarily during the initial emergency department visit.
Actively Recruiting
Acute headache, including migraine, tension-type, and cluster headaches, is a common and disabling reason for emergency department visits. This trial evaluates the effectiveness and safety of intravenous magnesium sulfate compared to intravenous paracetamol for treating acute non-traumatic headache. The study aims to clarify the optimal magnesium dose and its role in pain relief, with a focus on reducing headache intensity and improving patient outcomes in emergency care. Participants are randomly assigned to receive one of three treatments low-dose magnesium sulfate 2 g, high-dose magnesium sulfate 4 g, or paracetamol 1 g, each administered intravenously over 10-15 minutes. All infusions are prepared to maintain blinding, and continuous monitoring of vital signs is conducted during and after treatment. Rescue medication may be given starting 30 minutes after treatment if needed, and baseline magnesium levels will be measured to explore their relationship to treatment response. During the trial, participants will have their pain intensity assessed using the Visual Analog Scale at 60 minutes after treatment and followed for up to 120 minutes to monitor pain relief, use of rescue medication, adverse events, patient satisfaction, and emergency department length of stay. The studys primary outcomes focus on pain reduction and responder rates at 60 minutes. This trial is sponsored by the University of Monastir and plans to complete by the end of 2030.
Actively Recruiting
Researchers are evaluating the use of intravenous magnesium sulfate compared to a placebo for treating adults with non-traumatic acute headaches in the emergency department. This phase 3 randomized trial aims to assess how effective magnesium sulfate is when added to paracetamol for relieving headache pain. The study is led by the University of Monastir and focuses on patients aged 18 to 85 years presenting with acute headache symptoms not caused by trauma. Participants receive either 1 gram of paracetamol combined with a 20-minute infusion of 2 grams of magnesium sulfate in saline or 1 gram of paracetamol with a 20-minute infusion of saline alone as a placebo. The trial uses triple blinding to ensure unbiased results. The treatment is given intravenously in the emergency department setting. During the study, participants are closely monitored for headache relief over one day following treatment. Researchers will measure the primary outcome of headache response to magnesium sulfate within 24 hours. Secondary outcomes include comparing placebo effects. The study excludes individuals with certain medical conditions or medication use to ensure safety and accuracy. Participation duration includes the treatment and short-term observation period within the emergency setting.
Actively Recruiting
Researchers are evaluating the effects of olive leaf extracts atherolive on adults with type 2 diabetes. This study is conducted in emergency departments and external endocrinology and diabetology consultations at two hospitals. The trial compares atherolive to a placebo to better understand its impact on blood sugar control and related health markers. Participants will be randomly assigned to receive either atherolive or a placebo, both given as a 400 mg dose once daily for three months. Before treatment, patients undergo biological assessments including lipid profiles, blood sugar, creatinine levels, HbA1c for diabetics, and inflammatory markers like C-reactive protein. Continuous blood glucose monitoring using an iPro device is performed at the start to measure blood sugar variability. During the study, researchers will track continuous glucose monitoring results and Hemoglobin A1c levels over 90 days. Additional outcomes include changes in lipid balance and hospitalizations due to cardiovascular disease or adverse effects. Participants will be monitored for three months, with assessments to evaluate treatment effects and safety throughout.
Actively Recruiting
Renal colic is a common cause of severe abdominal pain leading to many emergency department visits. Researchers are evaluating whether oral non-steroidal anti-inflammatory drugs NSAI, specifically piroxicam, are beneficial as a second line treatment for patients discharged after initial renal colic treatment. This study compares the effects of piroxicam with acetaminophen and placebo to investigate pain recurrence, reconsultation rates, and hospital admissions. Participants are randomly assigned to one of three groups one receives 20 mg of piroxicam daily, another takes 1000 mg of acetaminophen daily, and the third group takes a placebo pill each day. All treatments last for five days. Patients will be contacted by telephone on the seventh day to assess the effectiveness and any side effects experienced. During the study, participants will be monitored through follow-up phone calls to evaluate pain recurrence, safety, and overall treatment impact within seven days. The main outcome measured is the efficacy of the oral NSAI within this one-week period. The study aims to provide clearer guidance on outpatient treatment options for renal colic. The total duration of participation includes the five-day treatment and follow-up contact on day seven.
Actively Recruiting
Heart failure HF is a major cause of hospitalization, rehospitalization, and death in adults over 65 years old. This research evaluates death and hospital readmission rates at 30 days and one year after hospital discharge among patients admitted to the emergency department with acute heart failure. It compares patients with heart failure with reduced ejection fraction HFrEF to those with preserved ejection fraction HFpEF. The study observes adult patients aged 18 to 80 admitted with acute heart failure to the emergency department of Monastir. It does not involve specific treatments but tracks outcomes such as death or readmission after discharge. The study period covers both short-term 30 days and long-term one year follow-up to understand prognosis in different types of heart failure. Participants will be monitored through their hospital records to record death or readmission within the specified timeframes. The research team collects data to measure these outcomes after discharge, with no investigational treatments administered. The total participation duration depends on the timing of discharge and follow-up up to one year after discharge.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to validate the Trauma-Related Immobilization-related Prophylaxis TRiPcast score in Tunisian adults with acute lower-limb injuries that require immobilization and outpatient care. The study aims to assess how well this score predicts the risk of developing symptomatic venous thromboembolism VTE, including deep vein thrombosis and pulmonary embolism. It also seeks to evaluate adherence to prescribed blood-thinning treatments and explore factors linked to adherence, bleeding events, and VTE outcomes. Participants will be grouped based on the anticoagulant treatment prescribed by their physician during routine care those receiving low-molecular-weight heparin LMWH, those prescribed direct oral anticoagulants DOACs, and those not receiving any pharmacological thromboprophylaxis. The study does not influence treatment decisions, which are made by the treating doctors. Patients must have acute lower-limb trauma requiring immobilization for at least 7 days and be managed as outpatients. During the study, participants will be followed for 45 days after enrollment to monitor the incidence of symptomatic VTE and bleeding events. Researchers will assess adherence to thromboprophylaxis at days 7, 30, and 45 using questionnaires including the Morisky Medication Adherence Scale. Clinical characteristics and factors affecting treatment adherence and outcomes will be analyzed. The study duration allows for thorough observation of VTE risk and medication adherence in this patient population.
1-10 of 11
1